{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IBRX",
  "name": "ImmunityBio, Inc.",
  "url": "https://frontierpicks.com/dossiers/IBRX/",
  "json_url": "https://frontierpicks.com/dossiers/IBRX.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "ImmunityBio's bladder-cancer drug Anktiva grew Q2 2026 net product revenue 92% year over year to $50.7 million, which keeps supporting the shares despite directors selling in October. Third-quarter revenue, due in a possible October preliminary release or the November report, settles whether the growth run continues.",
  "invalidation_trigger": "A daily close below $8.50, which would undo the late-September run through $10 and put the shares back toward the 50-day moving average. Third-quarter Anktiva net product revenue at or below Q2's $50.7 million would also end the case.",
  "catalyst_date": "2026-11-03",
  "pick": {
    "id": "P-2026-10-05-IBRX",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-05",
    "open_close": 10.38,
    "kill_level": 8.5,
    "kill_basis": "daily",
    "horizon_end": "2027-01-05",
    "last_date": "2026-10-09",
    "last_close": 10.51,
    "return_pct": 1.25,
    "spy_return_pct": 0.48,
    "excess_pp": 0.77,
    "kill_distance_pct": 23.6470588235294,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Insiders control about 66% of ImmunityBio's shares, per MarketBeat, which leaves a thin public float and can sharpen price moves in both directions.",
    "ImmunityBio's GAAP net loss has run far above its adjusted loss in 2026: $863.2 million against $167.3 million in the first half, per the company's 8-K.",
    "Executive Chairman Patrick Soon-Shiong also invests in other biotech companies, including PDS Biotechnology, and headlines about those ventures can move IBRX shares.",
    "ImmunityBio has released preliminary quarterly revenue ahead of full results, as on 2026-01-15 and 2026-04-09, so revenue news can arrive weeks before the formal report."
  ],
  "body_markdown": "## Current Thesis\nImmunityBio's bladder-cancer drug Anktiva is growing fast enough to keep supporting the shares, and the next read on that growth is the third-quarter revenue figure. The case turns on whether third-quarter net product revenue beats the second quarter's $50.7 million. The Food and Drug Administration (FDA) decision on a broader label, due by 2027-01-06, is the test after that.\n\nAnktiva's net product revenue rose from about $44.2 million in the first quarter of 2026 (preliminary figure, 8-K of 2026-04-09) to $50.7 million in the second quarter. The second-quarter figure was up 92% year over year and marked the eighth straight quarter of sequential growth, per the company's 2026-08-04 8-K. The company sells an approved product, yet the shares trade like a binary-catalyst name: FDA dates, label news and retail attention move the price more than the broad market does.\n\nThe narrative is maturing: the 2026-10-02 rally drew Benzinga coverage and two directors sold into it, and no new company release or filing has appeared since. The shares have steadied since the 2026-10-06 pullback, closing at $9.91 on 2026-10-08, up from $9.69.\n\n## Bull Case\n- **Eight straight quarters of sequential growth.** Q2 2026 net product revenue was $50.7 million, up 15% from Q1, the company's 2026-08-04 8-K shows. First-half revenue was $94.8 million, up 121% year over year.\n- **The company has reported revenue early before.** ImmunityBio published preliminary Q1 2026 revenue of about $44.2 million on 2026-04-09, nine days after the quarter closed, per its 8-K. A similar early release would put a third-quarter number in front of the market in October.\n- **A label expansion is under FDA review.** The FDA accepted a supplemental Biologics License Application (sBLA) for Anktiva plus BCG in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary disease and no carcinoma in situ. The target action date is 2027-01-06, per the 2026-08-04 release.\n- **More indications are queued.** The company plans a fourth-quarter 2026 filing for BCG-naive NMIBC carcinoma in situ, based on the fully enrolled QUILT-2.005 trial. The UAE's Emirates Drug Establishment approved Anktiva on 2026-07-29.\n- **Analysts mostly rate the shares a buy.** Jefferies upgraded the stock to Strong Buy on 2026-09-25. MarketBeat's consensus was Moderate Buy with a $14.20 average target on 2026-10-06, and StockAnalysis counted seven analysts averaging $12.57, from $7 to D. Boral Capital's $23.\n\n## Bear Case\n- Director Barry J.\n- Most of that notice had not been reported sold as of 2026-10-06.\n- **Losses are large against cash.** The Q2 2026 GAAP net loss was $230.4 million and the adjusted loss $81.0 million, per the 2026-08-04 8-K.\n\n## Setup & Price Structure\nThe shares closed at $9.91 on 2026-10-08, 14.2% below the 52-week high of $11.55 in adjusted daily closes. They were up 27.2% over three months. The 14-day relative strength index (RSI) stood at 64.6, below the 70 level often read as overbought, after falling from above 70 earlier in the week.\n\nThe late-September run carried the shares through $10, and the 2026-10-05 close of $10.38 marked the most recent high point before directors' sales were reported. The $8.50 level sits below the late-September breakout and would put the shares back toward their 50-day moving average. Crowding is visible in the insider selling into strength and the thin public float, with insiders holding about 66% of shares per MarketBeat.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-10-15 (est.) — possible preliminary Q3 2026 revenue.** The company released preliminary Q1 figures on 2026-04-09 and preliminary full-year 2025 figures on 2026-01-15. A figure above $50.7 million extends the growth run; a flat or lower figure breaks it.\n- **~2026-11-03 (est.) — Q3 2026 report.** Earnings Whispers lists 2026-11-16. The report updates cash after the Q2 GAAP loss of $230.4 million and shows the spending trend.\n- **~2026-12-31 (est.) — planned sBLA filing in BCG-naive carcinoma in situ.** A filing on schedule adds a third label-expansion path.\n- **2027-01-06 — FDA target action date for the papillary-disease sBLA.** Approval widens Anktiva's label; a rejection removes the main near-term expansion driver.\n\n## What Would Change Our Mind\nThird-quarter Anktiva net product revenue at or below Q2's $50.7 million, whether in a preliminary release or the full report, would break the growth case. An equity raise before the 2027-01-06 FDA date, or a complete response letter or review extension on the papillary sBLA, would also undercut it.\n\nOn price, a daily close below $8.50 would undo the late-September run through $10. Further Form 4 filings showing Simon selling most of his 560,000-share notice would add supply to a thin float. A preliminary Q3 figure well above $50.7 million with cash holding above $300 million would strengthen the case.\n\n## Correlation Notes\nImmunityBio sits in the precision-biotech group with Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA), Moderna (MRNA), Schrödinger (SDGR) and Recursion (RXRX). The group's attention cooled to maturing on 2026-10-09 after a brief pickup on 2026-10-04, which raises the bar for single-name moves. Iovance is the closest comparison: a commercial-stage immunotherapy company whose shares also move on launch revenue. IBRX's main drivers are company-specific (Anktiva sales, FDA dates, insider filings), so a group sell-off matters most if it coincides with weak Q3 revenue.",
  "first_seen": "2026-10-04",
  "last_analyzed": "2026-10-09T08:25:29+00:00",
  "last_synthesized": "2026-10-09",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}